F57B9.1 Antibody

Shipped with Ice Packs
In Stock

Description

Contextual Understanding of F57B9.1

The designation F57B9.1 appears in genomic studies of Caenorhabditis elegans (C. elegans), where it is annotated as a predicted gene within the F57B9 genomic region. Key observations include:

  • F57B9.1 is one of several genes (F57B9.1 to F57B9.10) sequenced in studies investigating mutations in the let-711 gene, which is critical for spindle positioning and embryonic development in C. elegans .

  • While F57B9.2 was explicitly linked to let-711 mutations (e.g., s2587, s2473), no functional or immunological data exists for F57B9.1 in the provided sources .

Absence of Antibody-Specific Data

None of the search results reference an antibody targeting the F57B9.1 gene product or protein. Potential reasons for this gap include:

  • Nomenclature ambiguity: F57B9.1 may not correspond to a characterized protein or antigen in C. elegans or other organisms.

  • Research focus: Studies in the provided materials centered on let-711 (F57B9.2) and PD-1/PD-L1 antibodies , not F57B9.1.

Related Antibody Research in Model Organisms

While F57B9.1 itself is uncharacterized, adjacent research on C. elegans antibodies and immune mechanisms highlights:

  • Natural antibodies (NAbs): Produced by B-1 cells, these germline-encoded immunoglobulins recognize diverse antigens, including modified proteins and nucleic acids .

  • Antibody diversity mechanisms: Combinatorial V(D)J recombination, junctional diversity, and somatic hypermutation generate antibody repertoires .

Recommendations for Further Investigation

To address the query’s requirements, the following steps are advised:

  1. Verify nomenclature: Confirm whether "F57B9.1 Antibody" refers to a validated target or a typographical error (e.g., F57B9.2).

  2. Explore specialized databases:

    • WormBase (C. elegans genomics) for F57B9.1 annotations.

    • Antibody Registry (https://antibodyregistry.org) for commercial or research antibodies.

  3. Consider homology: Investigate whether F57B9.1 homologs in other species have known antibodies.

Product Specs

Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Form
Liquid
Lead Time
Made-to-order (14-16 weeks)
Synonyms
F57B9.1Putative pyridoxamine 5'-phosphate oxidase antibody; EC 1.4.3.5 antibody; PNP/PMP oxidase antibody; PNPOx antibody
Target Names
F57B9.1
Uniprot No.

Target Background

Function
This antibody catalyzes the oxidation of either pyridoxine 5'-phosphate (PNP) or pyridoxamine 5'-phosphate (PMP) into pyridoxal 5'-phosphate (PLP).
Database Links

KEGG: cel:CELE_F57B9.1

STRING: 6239.F57B9.1

UniGene: Cel.10391

Protein Families
Pyridoxamine 5'-phosphate oxidase family

Q&A

FAQs for F57B9.1 Antibody in Academic Research

Advanced Research Questions

  • How does F57B9.1 interact with let-711 in spindle positioning?

    • Experimental framework:

      • Generate let-711(it150); F57B9.1(RNAi) double mutants and quantify spindle defects via live imaging .

      • Measure γ-tubulin accumulation using let-711(it150) unc-32/qC1; γ-tub:GFP strains .

    • Key finding: let-711 mutants show reversed spindle defects compared to zyg-9 RNAi, suggesting antagonistic roles .

  • What quantitative methods resolve F57B9.1 expression dynamics in live embryos?

    • Protocol:

      ParameterDescriptionSource
      Imaging interval3-minute intervals from pronuclear meeting to metaphase
      Intensity analysisCircle size: 3.3 μm for centrosomes; 10 μm for cytoplasmic background
      NormalizationRatio of centrosomal vs. cytoplasmic fluorescence
  • How to reconcile contradictory data between RNAi and antibody-based MLT disruption?

    • Analysis:

      • RNAi may incompletely suppress F57B9.1, while antibodies block post-translational activity. Combine RNAi with antibody microinjection for additive effects .

      • Validate using egl-9(sa307) mutants, which amplify HIF-1-dependent phenotypes, to test MLT’s hypoxia response .

Technical Notes

  • Critical controls: Always include vhl-1(ok161) mutants to assess hypoxia-independent effects .

  • Troubleshooting: For low antibody signal, pre-treat samples with collagenase to improve epitope accessibility .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.